Targeting the Binding Function 3 (BF3) Site of the Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1<i>H</i>-benzimidazole Derivatives
作者:Ravi Shashi Nayana Munuganti、Eric Leblanc、Peter Axerio-Cilies、Christophe Labriere、Kate Frewin、Kriti Singh、Mohamed D. H. Hassona、Nathan A. Lack、Huifang Li、Fuqiang Ban、Emma Tomlinson Guns、Robert Young、Paul S. Rennie、Artem Cherkasov
DOI:10.1021/jm3015712
日期:2013.2.14
The human androgen receptor (AR) is a proven therapeutic target in prostate cancer. All current antiandrogens, such as Bicalutamide, Flutamide, Nilutamide, and Enzalutamide, target the buried hydrophobic androgen binding pocket of this protein. However, effective resistance mechanisms against these therapeutics exist such as mutations occurring at the target site. To overcome these limitations, the
人类雄激素受体(AR)是前列腺癌中公认的治疗靶标。当前所有的抗雄激素药,例如比卡鲁胺,氟他米特,尼鲁米特和恩杂鲁米特,都靶向该蛋白的隐埋的疏水性雄激素结合袋。然而,存在对这些治疗剂的有效抗性机制,例如在靶位点发生的突变。为了克服这些限制,AR的称为结合功能3(BF3)的表面囊被表征为小分子治疗剂的替代靶标。许多AR抑制剂直接靶向BF3的先前由我们(标识药物化学杂志。 2011。54,8563)。在当前的研究中,基于先前的结果,我们开发了结构-活性关系,从而可以设计一系列2-((2-苯氧基乙基)硫基)-1 H-苯并咪唑和2-((2-苯氧基乙基)硫基) -1 H-吲哚作为铅BF3抑制剂。一些已开发的BF3配体对LNCaP和耐恩杂鲁胺的前列腺癌细胞系表现出显着的抗雄激素作用。